BCL2 and acute lymphoblastic leukemia: Scoring the response in relation to data for T-ALL on a DRP platform,8 the B-cell lymphoma 2 (BCL2) inhibitor BH-3 mimetic venetoclax (ABT-199) and the proteasome inhibitor bortezomib ranked in all three cases among the most active drugs (Fig 1B).